Valuation: Pfizer Limited

Market Cap 185B 1.93B 1.67B 1.58B 1.43B 2.68B 2.7B 18.84B 7.25B 93.75B 7.24B 7.08B 299B P/E 2027 *
22.9x
P/E 2028 * 19.7x
Enterprise Value 185B 1.93B 1.67B 1.58B 1.43B 2.68B 2.7B 18.84B 7.25B 93.75B 7.24B 7.08B 299B EV / Sales 2027 *
6.98x
EV / Sales 2028 * 6.39x
Free-Float
33.05%
Yield 2027 *
1.55%
Yield 2028 * 1.69%
1 day-0.47%
1 week-3.55%
Current month-14.12%
1 month-16.70%
3 months-10.67%
6 months-15.30%
Current year-19.35%
1 week 3,955.5
Extreme 3955.5
4,195.1
1 month 3,955.5
Extreme 3955.5
5,030
Current year 3,955.5
Extreme 3955.5
5,257
1 year 3,955.5
Extreme 3955.5
5,578.5
3 years 3,701
Extreme 3701
6,451.15
5 years 3,408
Extreme 3408
6,451.15
10 years 1,642
Extreme 1642
6,451.15
Manager TitleAgeSince
Chief Executive Officer 55 2023-04-02
Director of Finance/CFO - 2024-02-25
Chief Tech/Sci/R&D Officer - 2023-03-31
Director TitleAgeSince
Chairman 73 1999-12-06
Director/Board Member 63 2019-03-07
Director/Board Member 55 2023-04-02
Change 5-day change 1-year change 3-year change Capi.($)
-0.45%-3.55%-21.74%+2.79% 1.93B
-0.19%+1.09%+51.85%+97.36% 1,013B
+0.33%-0.71%+50.62%+65.50% 644B
+0.49%+5.73%+20.88%+72.92% 465B
-0.22%+2.88%+38.48%+37.98% 352B
-0.07%+1.82%+16.57%+23.39% 264B
-0.31%+2.02%+6.15%+10.75% 253B
-1.53%-4.46%+36.90%+44.08% 203B
-1.60%-5.51%-22.30%-58.60% 188B
+0.49%-0.23%+30.00%+93.34% 181B
Average -0.12%-2.17%+20.74%+38.95% 356.56B
Weighted average by Cap. +0.40%+0.01%+34.49%+59.39%

Financials

2027 *2028 *
Net sales 26.5B 276M 239M 226M 205M 384M 387M 2.7B 1.04B 13.44B 1.04B 1.01B 42.85B 28.92B 301M 261M 247M 224M 420M 423M 2.95B 1.13B 14.66B 1.13B 1.11B 46.76B
Net income 8.09B 84.34M 73.06M 69.08M 62.54M 117M 118M 824M 317M 4.1B 317M 310M 13.08B 9.36B 97.61M 84.55M 79.95M 72.38M 136M 137M 954M 367M 4.75B 367M 359M 15.14B
Net Debt - -
Logo Pfizer Limited
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Employees
1,244
Date Price Change Volume
26-09-16 4,023.50 -0.45% 26,477
26-09-15 ₹4,041.60 -0.46% 36,144
26-09-11 ₹4,060.20 -0.86% 138,685
26-09-10 ₹4,095.40 -1.81% 267,140
26-09-09 ₹4,171.00 -3.24% 125,703

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PFIZER Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!